ASTELLAS PHARMA INC.
Tokyo, Japan, February 5, 2015 - Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko
Hatanaka) announced the personnel changes and organization changes as below.
Name | New Title | Current Title |
Masaru Imahori | CEO's Office | Vice President, External Relations |
Name | New Title | Current Title |
Hirofumi Seki | CEO's Office | Divisional Senior Vice President, Technology Planning & Administration, Technology |
Yoshihiro Minami | CEO's Office | General Marketing Compliance Officer(Japan) |
Kenji Sumi | CEO's Office | General Manager, Tokyo Branch, Japan Sales & Marketing |
Chihiro Yokota | Head of Japan/Asia Development, Global Development, and Head of Japan Medical Affairs | Head of Japan/Asia Development, Global Development |
Makoto Takeuchi | Vice President, External Relations | Divisional Senior Vice President, Research Administration, Drug Discovery Research |
Name | Title (effective on April 1, 2015) |
Masaru Imahori | CEO's Office |
Name | Title (effective on April 1, 2015) |
Hirofumi Seki | CEO's Office |
Yoshihiro Minami | CEO's Office |
Kenji Sumi | CEO's Office |
Name | Title (effective on April 1, 2015) |
Mitsunori Matsuda | President, Technology |
Yukihiko Sato | President, Japan Sales & Marketing |
Chihiro Yokota | Head of Japan/Asia Development, Global Development, and Head of Japan Medical Affairs |
Wataru Uchida | President, Drug Discovery Research |
Makoto Takeuchi | Vice President, External Relations |
Name | Title (effective on April 1, 2015) |
Katsumi Ozawa | General Manager, Tokyo Branch, Japan Sales & Marketing |
Kazuhiro Sako | President, Astellas Ireland Co., Ltd |
Yukio Matsui | Senior Vice President, Global Marketing Strategy |
Nobuaki Tanaka | General Manager, Chiba Branch, Japan Sales & Marketing |
Toru Yoshimitsu | Corporate Vice President, Product and Portfolio Strategy |
Eisuke Nozawa | Vice President, Regulatory Affairs-Japan, Global Regulatory Affairs |
Fumiaki Sakurai | Corporate Vice President, Human Resources |
Taiji Sawamoto | Vice President, Clinical Pharmacology, Global Development |
2
7. Personnel Changes of Astellas Pharma Inc. effective on April 1, 2015Name | New Title | Current Title |
Shigeki Kawabata | Vice President, Evolving Medical Solutions | Vice President, Pharma Breakthrough |
Masaaki Usui | Vice President, Corporate Communications | President, Astellas Pharma Australia Pty Ltd |
Shinya Suda | Corporate Vice President, Information Systems (No change: only Japanese organization name will be changed) | Corporate Vice President, Information Systems |
Noriyuki Masuda | Divisional Senior Vice President, Research Administration, DDR | Executive Director, Research Portfolio & Science, Drug Discovery Research |
Minori Saitoh | Vice President, Drug Repurposing & Application Management | Senior Director, Research Portfolio & Science, Drug Discovery Research |
Tomonobu Koizumi | Vice President, Regenerative Medicine Labs., Drug Discovery Research | Vice President, Bioscience Research Labs., Drug Discovery Research |
Rika Hirota | Vice President, Bioscience Research Labs., Drug Discovery Research | Senior Director, Drug Safety Research Labs., Drug Discovery Research |
Shigeki Tanaka | Vice President, Japan/Asia Clinical Development 1, Japan/Asia Development | Vice President, Asian Development, Development |
Toshiyuki Sueyoshi | Vice President, Japan/Asia Clinical Development 2, Japan/Asia Development | Vice President, Clinical Development 2, Development |
Takuya Oshida | Vice President, Medical Science, Japan Medical Affairs | Vice President, Clinical Development 3, Development |
Keita Matsui | Vice President, Medical Research, Japan Medical Affairs | Vice President, Medical Affairs |
Naoko Sato | Vice President, Medical Information Center, Japan Medical Affairs | Vice President, Medical Information Center |
Hideki Shima | Divisional Senior Vice President, Technology Planning & Administration, Technology | President, Astellas Ireland Co., Ltd |
3
Kazutoshi Ban | Vice President, Biotechnology Labs., Technology | Senior Director, Biotechnology Labs., Technology |
Tadashi Hakomori | Divisional Senior Vice President, Pharmaceutical Research & Technology Labs., Technology | Senior Director, Yaizu Technology Center, Astells Pharma Tech Co., Ltd. |
Katsumi Ozawa | General Manager, Tokyo Branch, Japan Sales & Marketing | General Manager, Kyusyu Branch, Japan Sales & Marketing |
Atsuhito Iizumi | General Manager, Kobe Branch, Japan Sales & Marketing | Executive Director, Yokohama Branch, Japan Sales & Marketing |
Kazuhiko Hayashida | General Manager, Chugoku Branch, Japan Sales & Marketing | Executive Director, Kyoto Branch, Japan Sales & Marketing |
Kouji Ohba | General Manager, Kyusyu Branch, Japan Sales & Marketing | General Manager, Chugoku Branch, Japan Sales & Marketing |
Junko Komatsu | Vice President, Marketing & Business Management, Asia/Oceania Business | Executive Director, Product Marketing, Japan Sales & Marketing |
Yukio Matsui | Senior Vice President, Global Marketing Strategy | Vice President, Marketing & Business Management, Asia/Oceania Business |
Name | New Title | Current Title |
Kazuhiro Sako | President, Astellas Ireland Co., Ltd | Divisional Senior Vice President, Pharmaceutical Research & Technology Labs., Technology |
Charlotte Kremer | Executive Vice President, Medical Affairs Astellas Pharma Global Development, Inc. | Senior Vice President, Global Medical Affairs, Astellas Pharma Global Development, Inc. |
Bernie Zeiher | President, Global Development, Astellas Pharma Global Development, Inc. | Therapeutic Area Head and Executive Vice President, Global Development Astellas Pharma Global Development, Inc. |
4
9. Appointment of Staff Executive Director of Astellas Pharma Inc. effective on April 1, 2015Name | New Title | Current Title |
Shinya Yano | Staff Executive Director, Product and Portfolio Strategy | Executive Director, Product and Portfolio Strategy |
Shigenori Kawasaki | Staff Executive Director, Clinical Development Administration, Japan/Asia Development | Vice President, Clinical Development 1, Development |
Junichiro Honda | Staff Executive Director, Human Resources Development, Japan Sales & Marketing | Executive Director, Human Resources Development, Japan Sales & Marketing |
5
10. Organization ChangesMedical Affairs
In order to strengthen medical functions and organization management in Japan, Medical Affairs Division will be newly established and structuralize existing Medical Affairs and Medical Information. The names of Medical Affairs and Medical Information will change respectively to "Medical Science" and "Medical Information Center". In addition, the functions of Post-marketing Clinical Trial and Post-marketing Survey currently under Medical Affairs will move to under Medical Affairs Division, as newly established "Medical Research".
Pharma Breakthrough
The name of Pharma Breakthrough will change to "Evolving Medical Solutions". The new department name will enforce to reflect the department mission, collaborating with medically and pharmaceutically relevant field and providing the patients with breakthrough solutions.
Regenerative Medicine Labs.
The initial objective of Regenerative Medicine Unit established in April 2014 has been achieved. In order to reinforce research function to evaluate the regenerative medicine programs for clinical studies and in order to create a structure capable for more efficiently and effectively managing external collaboration with regenerative medicine-related authorities etc. as well as internal collaboration, the existing Regenerative Medicine Unit will be reorganized as a new organization named "Regenerative Medicine Labs".
Drug Repurposing & Application Management
Drug Repurposing & Application Management will be created as a new organization which will take a central role in maximization of the outcomes from drug repurposing activities conducted in Drug Discovery Research and appropriate management of research quality assurance in external collaborations as well as internal research in Drug Discovery Research.
Clinical Development
In order to strengthen clinical development functions for global strategic alignment including Asian countries and enabling higher mobility and flexible resource management, Clinical Development 1-3 and Asia Development restructured into "Japan/ Asia Clinical Development 1 and 2".
###
For inquiries or additional information
Astellas Pharma Inc. Corporate Communications
TEL: +81-3-3244-3201, FAX:+81-3-5201-7473
http://www.astellas.com/en
6
|
distributed by
|
